Photobiomodulation anti-inflammatory effect in COVID-19

Comparison of serum inflammatory mediators levels in patients affected by COVID-19 with and without photobiomodulation (PBM)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200616047799N1

Enrollment

Registered

2020-08-23

Start date

2020-06-30

Completion date

Unknown

Last updated

2020-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: Photobiomodulation with red light on patients' chest , back and neck for 3 days each day for 15 minutes. The device named "Neolys" manufactured by "Life+" company i

Eligibility

Sex/Gender

All

Age

15 Years to No maximum

Inclusion criteria

Inclusion criteria: COVID-19 Pneumonia Written consent Older than 15 years

Exclusion criteria

Exclusion criteria: Intubated patients Skin hypersensitivities or its history Psoriasis Inflammation of the site of PBM implementation

Design outcomes

Primary

Measure	Time frame
Interleukin-6. Timepoint: Immediately before intervention, 12, 24, 48, 72 hours after intervention. Method of measurement: ELISA immunologic kit (produced by R&D company).;IL-1-beta. Timepoint: Immediately before intervention, 12, 24, 48, 72 hours after intervention. Method of measurement: ELISA immunologic kit (produced by R&D company).;IL-8. Timepoint: Immediately before intervention, 12, 24, 48, 72 hours after intervention. Method of measurement: ELISA immunologic kit (produced by R&D company).;IL-10. Timepoint: Immediately before intervention, 12, 24, 48, 72 hours after intervention. Method of measurement: ELISA immunologic kit (produced by R&D company).;IL-12. Timepoint: Immediately before intervention, 12, 24, 48, 72 hours after intervention. Method of measurement: ELISA immunologic kit (produced by R&D company).;TNF-alpha. Timepoint: Immediately before intervention, 12, 24, 48, 72 hours after intervention. Method of measurement: ELISA immunologic kit (produced by R&D company).;TGF-beta. Timepoint: Immediately before intervention, 12, 24, 48, 72 hours after intervention. Method of measurement: ELISA immunologic kit (produced by R&D company).	—

Measure

Time frame

Interleukin-6. Timepoint: Immediately before intervention, 12, 24, 48, 72 hours after intervention. Method of measurement: ELISA immunologic kit (produced by R&D company).;IL-1-beta. Timepoint: Immediately before intervention, 12, 24, 48, 72 hours after intervention. Method of measurement: ELISA immunologic kit (produced by R&D company).;IL-8. Timepoint: Immediately before intervention, 12, 24, 48, 72 hours after intervention. Method of measurement: ELISA immunologic kit (produced by R&D company).;IL-10. Timepoint: Immediately before intervention, 12, 24, 48, 72 hours after intervention. Method of measurement: ELISA immunologic kit (produced by R&D company).;IL-12. Timepoint: Immediately before intervention, 12, 24, 48, 72 hours after intervention. Method of measurement: ELISA immunologic kit (produced by R&D company).;TNF-alpha. Timepoint: Immediately before intervention, 12, 24, 48, 72 hours after intervention. Method of measurement: ELISA immunologic kit (produced by R&D company).;TGF-beta. Timepoint: Immediately before intervention, 12, 24, 48, 72 hours after intervention. Method of measurement: ELISA immunologic kit (produced by R&D company).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehran Marashian

Shahid Beheshti University of Medical Sciences

mehranmarashian@gmail.com+98 21 2712 2604

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026